Our therapies
Targeted therapy, given with care
We provide Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) therapy for prostate cancer. Lutathera® (lutetium Lu 177 dotatate) therapy for neuroendocrine tumors will be offered at Excel in the future.
Radioligand therapy is a targeted radioactive medicine, given by IV, that seeks out cancer cells carrying a specific marker.

We give therapy infusions. We do not do scans.
Excel Theranostics is a stand-alone therapy clinic with no imaging on site. If you need a scan such as a PSMA PET, it is done at an imaging center, and our team reviews the results with you and your doctor.

Our first therapy
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)
Prostate cancer
- What it is
- A prescription radioligand therapy approved for adults with PSMA-positive metastatic prostate cancer, either (1) together with an androgen receptor pathway inhibitor (ARPI) when the cancer has not been treated with, or is still responding to, hormone therapy, or (2) after ARPI therapy when the cancer no longer responds to hormone therapy, whether taxane chemotherapy has already been given or is being delayed. The Prescribing Information lists the full approved uses.
- How it works
- PSMA is a protein found in much higher amounts on prostate cancer cells than on most normal cells. Pluvicto attaches to PSMA and brings radiation to the cells that carry it.
- Before treatment
- A PSMA PET scan, done at an imaging center, is used to confirm that the cancer is PSMA-positive.
- Treatment course
- Given by IV, typically once every 6 weeks for up to 6 doses.
Talk with your doctor to see if this treatment is right for you.
Prescribing Information for Pluvicto® (PDF) pluvicto.com, the official Pluvicto® patient site
Important Safety Information: see the full Prescribing Information for PLUVICTO® (PDF).
To report side effects, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Will be offered at Excel in the future
Lutathera® (lutetium Lu 177 dotatate)
Neuroendocrine tumors (NETs)
- What it is
- A prescription radioligand therapy approved for adults and children 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut NETs.
- How it works
- Many neuroendocrine tumors carry large numbers of somatostatin receptors. Lutathera attaches to these receptors and brings radiation to the tumor cells.
- Before treatment
- A somatostatin receptor scan, done at an imaging center, is used to confirm that the tumors carry the receptor.
- Treatment course
- Typically given as 4 doses about 8 weeks apart, each as an outpatient visit of several hours.
Lutathera® will be offered at Excel in the future. Until then, call us and we can help connect you with a center that provides it.
Talk with your doctor to see if this treatment is right for you.
Prescribing Information for Lutathera® (PDF) lutathera.com, the official Lutathera® patient site
Important Safety Information: see the full Prescribing Information for LUTATHERA® (PDF).
To report side effects, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
We're here to help you take the next step.
Call us, or send a note and our team will get back to you shortly.
